Discovery Laboratories, Inc. (DSCO) Begins Initial Phase of AFECTAIR® Launch

Discovery Laboratories, a specialty biotechnology company dedicated to raising the standard in respiratory critical care, announced today that the launch of its AFECTAIR® airway connector has been initiated. The AFECTAIR® airway connector is designed for infants needing aerosolized medication in neonatal or pediatric intensive care units (NICU and PICU, respectively), and it simplifies medication delivery for those critical care patients who need ventilatory support. This simplification is provided through the innovative process of introducing the medication directly at the patient interface.

The initial phase of the launch is the introduction of an AFECTAIR user experience program in leading U.S. critical care centers, representing approximately ten percent of the company’s targeted institutions. The institutions chosen were selected based on their status as centers of influence within the neonatal and pediatric critical care community. The beginning of the launch is dedicated to facilitating peer-to-peer exchange that will enable discussion amongst physicians and respiratory therapists regarding the advantages and proper utilization of this cutting edge device. The opening phase of the launch is expected to close soon after the first quarter of 2013, at which time Discovery Labs will start a more expansive introduction of AFECTAIR.

“We are very excited to formally introduce AFECTAIR to the neonatal and pediatric critical care community,” said Thomas F. Miller, Chief Operating Officer at Discovery Labs. “The AFECTAIR technology exemplifies Discovery Labs’ innovative spirit and progress toward advancing new standards in respiratory critical care.”

The AFECTAIR technology was developed as a component of the AEROSURF® development program and is a proprietary, disposable device that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support such as intermittent mechanical ventilation or continuous positive airway pressure. To date, in vitro studies suggest that the AFECTAIR technology may be an effective new solution for delivering aerosolized medications to infants receiving ventilatory support while providing healthcare professionals with a simplified alternative to current practices. According to national health statistics and internal market assessment data, it is estimated that each year approximately 355,000 pediatric patients in the United States are eligible to receive aerosolized medications while requiring ventilator support.

Discovery Labs is also pursuing European Conformity (CE) marking for potential commercialization of AFECTAIR for infants in the European Union (EU) in 2013.

For further information, please visit www.Discoverylabs.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html